Trial of SBRT With Concurrent Ipilimumab in Metastatic Melanoma
NCT02406183
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
13
Enrollment
OTHER
Sponsor class
Conditions
Melanoma
Effects of Immunotherapy
Adverse Effect of Radiation Therapy
Interventions
RADIATION:
Stereotactic body radiotherapy (SBRT)
DRUG:
Ipilimumab
Sponsor
Radiotherapie